Table 2.
Infection sites identified per viridans group streptococci (VGS) group.
| Infection site | Anginosus (n = 14) | Mitis (n = 20) | Sanguinis (n = 7) | Total (n = 43) |
|---|---|---|---|---|
| CLABSI | 2 (14.3%) | 12 (60.0%) | 3 (42.9%) | 18a (41.9%) |
| HAP | 2 (14.3%) | 3 (15.0%) | 2 (28.6%) | 7 (16.3%) |
| No focus identified | 6 (42.9%) | 0 (0.0%) | 1 (14.3%) | 7 (16.3%) |
| Abdominal abscess | 5 (35.7%) | 1 (5.0%) | 0 (0.0%) | 6 (14.0%) |
| MBI-LCBI | 0 (0.0%) | 4 (20.0%) | 0 (0.0%) | 5a (11.6%) |
| CAP | 1 (7.1%) | 0 (0.0%) | 1 (14.3%) | 2 (4.7%) |
| CNS infection | 1 (7.1%) | 0 (0.0%) | 0 (0.0%) | 1 (2.3%) |
| SSTI | 0 (0.0%) | 1 (5.0%) | 0 (0.0%) | 1 (2.3%) |
CLABSI, central-line associated bloodstream infection; HAP, healthcare associated pneumonia; MBI-LCBI, mucosal barrier injury-laboratory-confirmed bloodstream infection; CAP, community-acquired pneumonia; CNS, central nervous system; SSTI, skin and soft tissue infection.
a
S. salivarius is not shown in the table, but one is included in the total count for CLABSI and one MBI-LCBI.